Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

키워드

참고문헌 (17)

1. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications", Clinical and Molecular Hepatology, 24(3), pp.169~229 (2018), 대한간학회
2. AASLD, "IDSA HCV Guidance Panel", Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, 2015, pp.62, 932~954
3. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)[DOI]
4. Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 369, pp.678~679 (2013)[DOI]
5. Zeuzem S, "Sofosbuvir and ribavirin in HCV genotypes 2 and 3", N Engl J Med, 370, pp.1993~2001 (2014)[DOI]
6. Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)[DOI]
7. Ippolito AM, "HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: the ITAL-C network study", Dig Liver Dis, 49, pp.1022~1028 (2017)[DOI]
8. Welzel TM, "Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study", Gut, 66, pp.1844~1852 (2017)[DOI]
9. Mangia A, "Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience", J Hepatol, 66, pp.711~717 (2017)[DOI]
10. Foster GR, "Efficacy of sofosbuvir plus ribavirin with or without peginterferonalfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection", Gastroenterology, 149, pp.1462~1470 (2015)[DOI]
11. Ahn SH, "A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus", J Viral Hepat, 23, pp.358~365 (2016)[DOI]
12. Kao JH, "A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection", Liver Int, 36, pp.1101~1107 (2016)[DOI]
13. Omata M, "Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial", J Viral Hepat, 21, pp.762~768 (2014)[DOI]
14. "Clin Mol Hepatol", 2017, 62~63
15. Young Min Kim, "Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study", Clinical and Molecular Hepatology, 24(3), pp.311~318 (2018), 대한간학회
16. "Sofosbuvir therapy and IFNL4 genotype;Medical Genetics Summaries"[URL]
17. Jung YK, "Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans", J Clin Gastroenterol, 47, pp.644~650 (2013)[DOI]

관련 논문AI추천